[1]王 晖,赵文景,孟 元,等.保肾通络方治疗糖尿病肾脏病气阴两虚兼血瘀证疗效及对患者血清isthmin-1水平的影响[J].陕西中医,2025,46(5):620-623.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.009]
　WANG Hui,ZHAO Wenjing,MENG Yuan,et al.Research of Baoshen Tongluo decoction on serum isthmin-1 of diabetic kidney disease with qi yin deficiency and blood stasis[J].,2025,46(5):620-623.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.009]
点击复制

保肾通络方治疗糖尿病肾脏病气阴两虚兼血瘀证疗效及对患者血清isthmin-1水平的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年5期
页码:
620-623
栏目:
临床研究
出版日期:
2025-05-05

文章信息/Info

Title:
Research of Baoshen Tongluo decoction on serum isthmin-1 of diabetic kidney disease with qi yin deficiency and blood stasis
作者:
王 晖; 赵文景; 孟 元; 王悦芬; 蔡 朕; 郑桂敏; 江心灿; 崔方强
(首都医科大学附属北京中医医院,北京 100010)
Author(s):
WANG Hui; ZHAO Wenjing; MENG Yuan; WANG Yuefen; CAI Zhen; ZHENG Guimin; JIANG Xincan; CUI Fangqiang
(Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China)
关键词:
糖尿病肾脏病;  终末期肾病;  保肾通络方;  尿素氮;  血清Ism-1;  尿足细胞
Keywords:
Diabetic kidney disease;  End stage renal disease;  Baoshen Tongluo decoction;  Blood urea nitrogen;  Serum isthmin-1;  Urinary podocytes
分类号:
R 587.2
DOI:
DOI:10.3969/j.issn.1000-7369.2025.05.009
文献标志码:
A
摘要:
目的:观察保肾通络方对于气阴两虚兼血瘀证糖尿病肾脏病(DKD)患者的临床疗效及其对患者血清isthmin-1表达、尿足细胞数目的影响。方法:收集DKD(G2A3期)患者60例,随机分为治疗组和对照组,两组患者均给予饮食控制、降糖、降压等基础治疗,而治疗组在基础治疗的同时加服保肾通络方,干预12周,后对两组患者治疗前后24 h尿蛋白(24 h UTP)、尿白蛋白肌酐比(ACR)、血清肌酐(Scr)、血清尿素氮(BUN)、肾小球滤过率(eGFR)、中医证候积分、尿足细胞数目及血清isthmin-1水平进行比较。结果:治疗组总有效率明显高于对照组(P<0.05),两组患者经治疗后,治疗组患者的24 h UTP、尿ACR、血清肌酐、血清尿素氮及中医证候积分均较对照组明显降低(P<0.01),eGFR明显升高(P<0.01)。与对照组相比,治疗组患者治疗后的尿足细胞数目及血清isthmin-1水平明显降低(P<0.01)。结论:保肾通络方可以降低DKD患者蛋白尿、保护肾功能,同时可以降低血清isthmin-1水平及减少尿足细胞数目。
Abstract:
Objective:To observe the effect of Baoshen Tongluo decoction on serum isthmin-1 and urinary podocytes of diabetic kidney disease patients.Methods:A total of 60 DKD(G2A3)patients were randomly divided into control group and treatment group.Patients in control group were received with basic treatment.Patients in treatment group were received with Baoshen Tongluo decoction on along with basic treatment.The treatments were lasted for 12 weeks.Scr,BUN,UACR,24 h UTP,eGFR,serum isthmin-1 and urinary podocytes were detected.Clinical symptom scores and therapeutic efficacy were compared between the two groups before and after treatment.Results:The total effective rate of treatment group was higher than that in the control group(P<0.05).After treatment,the scores of TCM symptoms,24 h UTP,UACR,Scr,and BUN were lower in the treatment group than those in the control group(P<0.01).Compared with control group,eGFR was significantly increased in treatment group after the treatment(P<0.01).After the treatment,the level of serum isthmin-1 and urinary podocytes were significantly decreased in treatment group compared with control group(P<0.01).Conclusion:Baoshen Tongluo decoction on can significantly decrease proteinuria and improved renal function in DKD,partly via decreasing serum isthmin-1 and urinary podocytes of DKD.

参考文献/References:

[1] 殷晋华,杨晓燕,李鹏丽,等.2型糖尿病患者胰岛细胞自身抗体、抗谷氨酸脱羧酶抗体水平与糖尿病微血管并发症的关系[J].保健医学研究与实践,2024,21(5):60-64,84.
[2] LIN Y C,CHANG Y H,YANG S Y,et al.Update of pathophysiology and management of diabetic kidney disease[J].J Formos Med Assoc,2018,117(8):662-675.
[3] 左星博,郑佳新.肾脏疾病中DNA甲基化的潜在作用机制[J].保健医学研究与实践,2023,20(9):8-18.
[4] DE BOER I H,GAO X,CLEARY P A,et al.Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes:The DCCT/EDIC study[J].Clin J Am Soc Nephrol,2016,11:1969.
[5] WATANABE K,SATO E,MISHIMA E,et al.What's new in the molecular mechanisms of diabetic kidney disease:Recent advances[J].Int J Mol Sci,2022,24(1):570.
[6] JIANG S,FANG J,LI W.Protein restriction for diabetic kidney disease[J].Cochrane Database Syst Rev,2023,1(1):CD014906.
[7] XU M,FENG R,YIN X,et al.Glomerular filtration rate in patients with type 2 diabetes mellitus:Is serum isthmin-1 level a possible link?[J].BMJ Open Diabetes Res Care,2023,11(4):e003402.
[8] 郭弋凡,崔方强,孙雪艳,等.益气滋肾通络法治疗糖尿病肾脏病探讨[J].北京中医药,2020,39(11):1154-1156.
[9] 崔方强,王悦芬,孟元,等.保肾通络方含药血清对高糖培养足细胞Nephrin、 Desmin蛋白表达及细胞凋亡的影响[J].陕西中医,2023,44(8):995-999.
[10] 中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南 [J].中华肾脏病杂志,2021,37(3):255-304.
[11] ANDRASSY K M.Comments on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J].Kidney Int,2013,84(3):622-623.
[12] 中华中医药学会.糖尿病肾病中医防治指南[J].中国中医药现代远程教育,2011,9(4):151-153.
[13] 中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:233-237.
[14] 中华中医药学会肾病分会.糖尿病肾病诊断、辨证分型及疗效评定标准(试行方案)[J].上海中医药杂志,2007,41(7):7-8.
[15] FU H,LIU S,BASTACKY S I,et al.Diabetic kidney diseases revisited:A new perspective for a new era[J].Mol Metab,2019,30:250-263.
[16] 雷强,夏绮梦,杜春容.老年维持性血液透析患者血清GDF11和Cdc42变化与心血管事件的相关性研究[J].临床肾脏病杂志,2024,24(8):660-666.
[17] DE BOER I H,AFKARIAN M,RUE T C,et al.Renal outcomes in patients with type 1 diabetes and macroalbuminuria[J].J Am Soc Nephrol,2014(25):2342.
[18] SAWAF H,THOMAS G,TALIERCIO J J,et al.Therapeutic advances in diabetic nephropathy[J].J Clin Med,2022,11(2):378.
[19] JIANG A,SONG A,ZHANG C.Modes of podocyte death in diabetic kidney disease:An update[J].J Nephrol,2022,35(6):1571-1584.
[20] 刘雪芳,夏碧文,熊静妮,等.复方血栓通胶囊对早期糖尿病肾病患者肾功能、尿足细胞及Nephrin蛋白的影响[J].新中医,2022,54(6):119-124.
[21] LIANG J Y,WEI H J,TANG Y Y.Isthmin:A multifunctional secretion protein[J].Cytokine,2024,173:156423.
[22] 徐明月.2型糖尿病患者血清Isthmin 1水平与糖尿病肾病的相关性研究[D].济南:山东大学,2023.
[23] WANG C,XU M,FENG R,et al.Serum isthmin-1 levels are positively and independently correlated with albuminuria in patients with type 2 diabetes mellitus[J].BMJ Open Diabetes Res Care,2022,10(5):e002972.
[24] 张炜捷,朱戎.基于足细胞上皮-间充质转化探讨中医药对慢性肾脏疾病作用机制及研究进展[J].陕西中医,2024,45(9):1294-1297.
[25] 李雨婷,蔡旭东,林晓蒙,等.温阳活血法改善微循环治疗糖尿病肾病研究进展[J].陕西中医,2025,46(1):139-141,145.

相似文献/References:

[1]盛凌黎,曹子怡,郭小平,等.加味陈氏糖肾方治疗糖尿病肾脏病G3-4A1-3期合并脂代谢紊乱临床研究[J].陕西中医,2025,46(2):192.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.009]
　SHENG Lingli,CAO Ziyi,GUO Xiaoping,et al.Clinical study of modified CHEN's Tangshen decoction in the treatment of diabetic kidney disease G3-4A1-3 complicated with lipid metabolism disorder[J].,2025,46(5):192.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.009]

备注/Memo

备注/Memo:
[基金项目]国家自然科学基金资助项目(81703989); 北京市属医院科研培育计划(PZ2025012); 北京市属医院科研培育计划项目(PZ2019013); 首都医科大学科研培育基金(自然类)资助项目(PYZ22163)
更新日期/Last Update: 2025-05-08